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 SUMMARY 
 Indications.  The only U.S. Food and Drug Administration 
(FDA)-approved indication for the use of doxycycline for 
malaria is for prophylaxis of  Plasmodium falciparum in short-
term travelers (< 4 months) to areas with chloroquine and/or 
pyrimethamine-sulfadoxine-resistant strains. Although not 
FDA approved, doxycycline is recommended for prophylaxis 
of other species of malaria 1 and may be used long term. When 
used in conjunction with other medications, doxycycline can be 
used for the treatment of malaria in non-pregnant adults and 
children ≥ 8 years of age: with quinine sulfate for uncompli-
cated, chloroquine-resistant  P. falciparum ; with both quinine 
sulfate and primaquine for uncomplicated chloroquine-resis-
tant  Plasmodium vivax ; and with parenteral quinidine for 
severe malaria. 2 
 Dosing.  Available in multiple dosage forms and strengths, 
doxycycline tablets or capsules of 100 mg are most often 
used for malaria prophylaxis or treatment. Tablets or cap-
sules should be swallowed with an adequate amount of fluid 
and should be taken with food. Intravenous (IV) formulation 
is available for patients unable to take oral medications for 
treatment. For IV, avoid rapid administration. 
 Adults.  Prophylaxis: 100 mg base once daily starting 1–2 days 
before travel, then daily during travel, and daily for 4 weeks 
after leaving the malarious area. 
 Treatment: 100 mg twice a day for 7 days; must be used in 
conjunction with a fast acting schizontocide. Primaquine is 
also required if treating  P. vivax or  Plasmodium ovale . 
 Children.  For children ≥ 8 years of age. 
 Prophylaxis: 2.2 mg/kg (up to adult dose of 100 mg) daily 
starting 1–2 days before travel, daily during travel, and daily 
for 4 weeks after leaving the malarious area. 
 Treatment: 2.2 mg/kg (up to adult dose of 100 mg) twice a 
day for 7 days; must be used in conjunction with a fast acting 
schizontocide. Primaquine is also required if treating  P. vivax 
or  P. ovale . 
 Efficacy.  Prophylaxis: Protective efficacy of doxycycline has 
been shown in three randomized placebo-controlled trials to 
be between 92% and 96% for  P. falciparum and 98% for pri-
mary  P. vivax infection. 
 Treatment: When used in combination with a fast acting sch-
izontocide, treatment efficacy of doxycycline has been shown 
to be 96–100% in three open-label trials. 
 Pharmacokinetics.  Limited data suggest that milk and other 
dairy products may limit the bioavailability of doxycycline. 
It is recommended to separate doxycycline and ingestion of 
dairy products by 2–3 hours. 
 Adverse drug reactions.  Most common mild/moderate 
adverse drug reactions (ADRs): nausea, vomiting, abdominal 
pain, photosensitivity, and vaginitis. Women prone to candidal 
vaginitis should consider carrying a self-treatment course 
of an anti-fungal. Severe ADRs are uncommon and include 
esophagitis and esophageal ulcerations. Doxycycline mono-
hydrate has been observed to have less gastrointestinal side 
effects than doxycycline hyclate. 
 Contraindications.  Doxycycline is contraindicated in those 
who have known hypersensitivity to tetracyclines. 
 Drug interactions.  Decreased absorption of doxycycline can 
occur if taken concurrently with medications with divalent or 
trivalent cations such as antacids, laxatives, and oral iron prep-
arations. Although the current FDA label states “concurrent 
use of tetracycline may render oral contraceptives less effec-
tive,” recent studies have failed to show a significant asso-
ciation between oral contraceptive failure and tetracyclines. 
Tetracyclines may potentiate the effect of oral anticoagu-
lants, therefore patients on oral anticoagulants should have 
prothrombin times monitored closely and dose adjusted as 
needed. Concurrent use of tetracyclines and methoxyflurane 
anesthesia is not recommended. Barbiturates, carbamazepine, 
and phenytoin decrease the half-life of doxycycline. 
 Warnings.  Pregnancy category D: Do not use in pregnancy 
except for the treatment of life-threatening multidrug-resis-
tant  P. falciparum when no other treatment options are avail-
able. Not recommended for children < 8 years of age. 
 Use during breastfeeding.  Excreted in low concentrations in 
breast milk; noted to be compatible with breastfeeding by the 
American Academy of Pediatrics. 
 INTRODUCTION 
 Doxycycline is a broad-spectrum bacteriostatic agent synthet-
ically derived from naturally occurring tetracyclines produced 
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by  Streptomyces sp. bacteria. 3 Doxycycline was invented and 
clinically developed in the early 1960s by Pfizer Inc ., New 
York, NY, and marketed under the brand name Vibramycin. 
Vibramycin received FDA approval in 1967, becoming Pfizer’s 
first once-a-day broad-spectrum antibiotic. The additional 
indication for malaria prophylaxis was obtained in 1994 with 
a supplemental New Drug Application. Tetracyclines were 
first reported efficacious against drug-resistant malaria in the 
1970s. 4 , 5 Early studies examined the effectiveness of tetracy-
cline, minocycline, and doxycycline as antimalarials. 4– 8 The evi-
dence for minocycline beyond these early studies is limited, 
and the four times per day dosing of tetracycline may make 
adherence difficult. Of the tetracyclines, doxycycline has the 
most evidence for its effectiveness as an antimalarial. 
 RECOMMENDED USES AND DOSING OF 
DOXYCYCLINE 
 Doxycycline can be used by travelers to all malaria-endemic 
areas for malaria prophylaxis. When used in conjunction 
with other medications, doxycycline can also be used to treat 
malaria. 
 Prophylaxis.  Doxycycline can be used for the prevention 
of malaria in travelers to malaria-endemic areas and is a good 
option for areas with chloroquine or multidrug-resistant  P. fal-
ciparum . For prophylaxis, doxycycline is taken once daily begin-
ning 1–2 days before travel, while in malarious areas, and for 
4 weeks after leaving. Daily dosage for children ≥ 8 years of age 
is 2.2 mg/kg (not to exceed the adult dose of 100 mg) and for 
adults 100 mg. 
 Treatment.  Doxycycline should always be used in conjunc-
tion with another drug for treatment of malaria. Quinine with 
doxycycline can be used for uncomplicated malaria caused by 
chloroquine-resistant  P. falciparum or  P. vivax . When used for 
severe malaria doxycycline should be used with intravenous 
quinidine. The treatment dose of doxcycyline in adults is 100 mg 
twice a day and for children 2.2 mg/kg twice a day up to a 
maximum of 100 mg twice daily. For those unable to tolerate 
oral medications, doxycycline is available in a parenteral form 
and can be made in concentrations between 0.1 and 10 mg/mL. 
If pain occurs while receiving doxycycline intravenously, it is 
recommended to use more dilute concentrations (no lower 
than 0.1 mg/mL) infused at rates no higher than 1 mg/min 9 ; 
switch to an oral formulation once the patient is able to tol-
erate medications by mouth. If treating  P. vivax or  P. ovale , 
in addition to the aforementioned drugs, primaquine must 
also be given to prevent relapses (see Pharmacodynamics 
section). 
 EFFICACY AND EFFECTIVENESS 
 The emergence of chloroquine-resistant  P. falciparum in the 
1960s spurred efforts to examine alternative medications such 
as tetracyclines with antimalarial activity. Early studies exam-
ined the treatment and prophylactic efficacy of tetracyclines 
such as doxycycline, tetracycline, and minocycline against 
chloroquine-resistant  P. falciparum . Since these earlier stud-
ies, the preponderance of literature on efficacy of tetracyclines 
as antimalarials has focused on doxycycline. 
 Overall, studies have showed that doxycycline is a slow-
acting blood schizontocidal agent, had partial causal effects 
and no sporontocidal or gametocytocidal effects, and is effec-
tive in the treatment and prevention of malaria (prophylaxis 
 Table 1 ). 10 –18  Doxycycline 100 mg daily has been shown to be 
highly effective as a blood schizonticidal agent, meaning that 
it kills the asexual, erythrocytic stages of the malaria para-
site. 10, 12– 21 Three randomized, double-blinded, placebo-con-
trolled studies showed that in semi-immune patients, 100 mg 
of doxycycline daily had a protective efficacy of 84% (95% 
confidence interval [CI] = 79.9–97.5%), 92.6% (95% CI = 
79.9–97.5%), and 96% (95% CI = 85.4–99.6%) for  P. falci-
parum infections. 10, 11, 18 One of these studies found that doxy-
cycline had a 98% (95% CI = 88.0–99.9%) protective efficacy 
against primary  P. vivax infection, 18 but did not examine pro-
tective efficacy against relapses. Another randomized, dou-
ble-blinded, placebo-controlled study showed a 99% (95% 
CI = 94–100%) protective efficacy of doxycycline 100 mg 
daily for  P. falciparum in 67 non-immune Indonesian sol-
diers. 13 However, in two of these studies, participants were 
not followed up after leaving the malaria-endemic areas, 
and it was unclear if prophylactic medications were contin-
ued after leaving. One open-label trial followed non-immune 
patients for 3 months after returning from a malaria-endemic 
country. Patients had received 100 mg of daily doxycycline 
while abroad. Of these 171 patients, only 5 (0.6%) developed 
 P. falciparum malaria during the follow-up period. Of these 
5, one developed malaria while on prophylaxis and 4 devel-
oped symptoms after discontinuation of prophylaxis during 
the 3 months of observation upon returning to a malaria-free 
country. 12 
 Other studies have also shown doxycycline to have inade-
quate causal activity, or activity against the liver stage of the 
malaria parasite, which has implications for doxycycline’s 
post-exposure course. 5, 22– 24 One randomized, double-blinded, 
placebo-controlled trial examined the efficacy of doxycycline 
prophylaxis for  P. falciparum malaria when taken by indi-
viduals exposed to mosquitoes infected with  P. falciparum . 
Doxycycline was taken daily 3 days before exposure and for 
6 days post exposure. Four of 12 persons taking that preven-
tive regimen developed falciparum malaria 15–24 days after 
completing medications; the protective efficacy was 67% 
(95% CI = 35–90%). 23 Another study found that of 60 soldiers 
who received 100 mg of doxycycline a day before deploy-
ment, 6 weeks during their deployment, and for 3 days after 
their return, none had falciparum malaria, whereas two devel-
oped vivax malaria. 16 These studies suggest that doxycycline 
has some tissue schizontocidal activity for  P. falciparum , but is 
insufficient for causal prophylaxis. Doxycycline would there-
fore have to be continued for a sufficient amount of time post 
exposure for successful suppression of parasites that emerge 
from the liver. Studies have observed that 5, 22– 24 malaria devel-
oped within 3–4 weeks post exposure. It is therefore rec-
ommended that doxycycline prophylaxis be continued for 
4 weeks post exposure. 
 Doxycycline’s limited activity in the liver stages of  Plas-
modium also means that it does not kill  P. vivax hypnozoites. 
Although very effective for preventing primary  P. vivax infec-
tions, doxycycline is not effective at preventing relapses. 
 The dose of doxycycline required to achieve successful 
malaria prophylaxis was also examined. The efficacy of half-
dose doxycycline (50 mg/day,  N = 67) was compared with 
full-dose doxycycline (100 mg/day,  N = 77). One open-label, 
randomized, controlled trial found that full-dose doxycycline 
was significantly more effective in prevention of  P. vivax, 
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however the study was not powered to detect a difference 
between the two doses of doxycycline in preventing  P. falci-
parum infections. 14 Another study examined the effectiveness 
of full-dose and half-dose doxycycline under operational con-
ditions; adherence to medications was not enforced. Although 
adherence to full versus half-dose doxycycline was not exam-
ined, the study found that on average 73% of the doxycycline 
regimen was taken and that half-dose (33% infected) was 
significantly less effective than full-dose doxycycline (19% 
infected) at preventing both  P. falciparum and primary  P. vivax 
infection. 17 
 Treatment ( Table 2 ). 5 , 26 –29   Doxycycline has been shown to 
be a slower acting blood schizonticide during the course of an 
acute  Plasmodium infection relative to other antimalarials. 30 
However, doxycycline achieves good treatment efficacy when 
given with rapidly acting shizontocidal drugs such as quinine 
or quinidine. Studies have reported parasite clearance times 
( P. falciparum ) between 3.8 and 6.0 days and fever clearance 
times between 3.6 and 4.0 days in patients treated with only 
tetracycline or doxycycline. 4, 7, 25, 26 These clearance times are 
longer than those observed in patients given quinine alone 
with parasite and fever clearance times of 2.6 days and 1.9–2.6 
days, respectively. 31, 32 In terms of treatment efficacy, in patients 
given doxycycline or tetracycline alone for  P. falciparum , 
cure rates between 75% and 100% have been reported. 5, 7 
Therefore, the slowness with which tetracyclines act make 
them of limited usefulness as a monotherapy in  P. falciparum 
infections. 5, 7 The usefulness of tetracycline when given with a 
faster acting schizontocidal drug, quinine, was studied when 
decreased effectiveness of quinine was observed in Southeast 
Asia. 7, 32, 33 Two open-label trials, one non-randomized and 
the other randomized, gave subjects quinine (640 mg three 
times daily for 3 days, and 600 mg four times daily for 7 days, 
respectively) and tetracycline (250 mg four times daily for 
10 days) and found treatment efficacies between 96% and 
98% with average parasite clearance times between 3 and 
 Table 1 
 Efficacy of doxycycline for prophylaxis * 
Country (population) Study type
Sample size 
on doxycycline
Duration of 
prophylaxis Efficacy (95% CI, if reported)
Kenya (semi-immune) 10 Randomized, double-blind, comparators = 
azithromycin daily ( N = 59), azithromycin 
weekly ( N = 58), and placebo
55 10 weeks Doxycycline: 92.6% (79.9–97.5%)
Azithromycin daily: 82.7% (68.5–91.1%)
Azithromycin weekly: 64.2% 
(47.1–77.1%) azithromycin weekly
Kenya (semi-immune, 
children aged 9–14) 11 
Randomized, double-blind, comparators = 
primaquine daily ( N = 32), proguanil daily 
plus chloroquine weekly ( N = 37), vitamin 
daily plus weekly mefloquine ( N = 30), 
vitamin alone ( N = 34)
32 11 weeks Doxycycline: 84% (66–92%)
Primaquine: 85% (68–93%)
Mefloquine: 77% (55–88%)
Chloroquine plus proguanil: 54% 
(25–72%)
Gabon and Central African 
Republic (non-immune) 12 
Randomized, open-label, 
comparator = CP ( N = 270)
171 Travel: 
4 months
Doxycycline: 97.0%
CP: 98.9%
Irian Jaya (non-immune) 13 Randomized, double-blind, 
comparator = MQ ( N = 68) 
and placebo
67 13 weeks Doxycycline: 99% (94–100%) overall, 
98% (88–100%) for  P. falciparum , 
100% (90–100%) for  P. vivax 
MQ: 100% (96–100%) overall, 100% 
(93–100%) for  P. falciparum , 100% 
(91–100%) for  P. vivax 
Thai–Burmese border 
(semi-immune children 
aged 10–16 years) 14 
Randomized, open-label, 
comparators = half-dose 
doxycycline ( N = 77), placebo
67 5 months Full-dose: 5 cases/1070 person-weeks
Half-dose: 20 cases/1176 person-weeks
Thai-Burmese border 
(semi-immune children 
aged 19015 years) 15 
Randomized, open-label, 
comparator = CQ ( N = 93)
95 9 weeks Doxycycline: 5 cases/597 person-weeks
CQ: 31 cases/488 man-weeks
Papua New Guinea (PNG), 
Malaysia, Thailand 
(non-immune) 16 
Open-label, comparators = MQ ( N = 40, 
PNG), doxycycline + PQ ( N = 69, 
PNG), doxycycline + CQ ( N = 125, 
Malaysia and Thailand)
60 6 weeks Doxycycline ( N = 60): 100% for  
P. falciparum , 96.7% for  P. vivax 
55 3 weeks Doxycycline ( N = 55): 100% for  
P. falciparum , 76.4% for  P. vivax 
MQ: 100% for  P. falciparum , 90% for 
 P. vivax 
Doxycycline + PQ: 100% for both 
 P. falciparum and  P. vivax 
Thai-Kampuchean border 
(non-immune) 17 
Randomized, open-label, comparators = 
half-dose doxycycline ( N = 243) or 
phyrimethamine + dapsone ( N = 123), 
adherence observed but not enforced
243 17 weeks Doxycycline + CQ: 
81% (Adherence 73% 
for both doxycycline groups)
Irian Jaya, Indonesia 
(non-immune) 18 
Randomized, double-blind, placebo-
controlled, comparators: azithromycin 
( N = 148), placebo
75 20 weeks Doxycycline: 97.1% (91.2–99.4%) 
overall, 96.3% (85.4–99.6%) 
 P. falciparum , 98.0% (88.0–99.9%) 
 P. vivax 
Azithromycin: 84.7% (75.5–90.7%) 
overall, 71.6% (50.3–83.8%) 
 P. falciparum , 98.9% (93.1–99.9%) 
 P. vivax 
 *  CI = confidence interval; CP = chloroquine-proguanil; MQ = mefloquine; PQ = primaquine; CQ = chloroquine. 
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3.6 days and a fever clearance time of 2.6 days. 7, 34 Furthermore, 
one study observed that tetracycline contributed to the main-
tenance of plasma quinine levels above the minimum inhibi-
tory concentration during the treatment period. 35 It was then 
extrapolated from these studies that quinine plus doxycycline 
would also be an effective malaria treatment regimen. More 
recently, an open-label trial showed 100% cure of all subjects 
given quinine (10 mg/kg three times a day for 3 to 7 days) and 
doxycycline (100 mg twice a day for 7 days) for treatment of 
uncomplicated  P. falciparum malaria. 29 Therefore, doxycycline 
should be given with a rapidly acting schizontocide for timely 
and effective malaria treatment. 
 PHARMACOKINETICS AND 
PHARMACODYNAMICS 
 Pharmacokinetics.  An oral dose of 100–200 mg of doxy-
cycline is almost completely absorbed in the duodenum and 
stomach and is detectable in the blood 15–30 minutes after 
administration. Following a 200 mg oral dose, peak concen-
trations of ~2.6 μg/mL are reached at ~2 hours, but this may 
vary as gastrointestinal (GI) absorption rates can differ among 
individuals. 3, 36, 37 Doxycycline, being highly lipophilic, is read-
ily transported across cell membranes, resulting in widespread 
distribution in body tissues and fluids. 37 Doxycycline binds 
to serum proteins, localizes in the bone marrow, liver, and 
spleen, crosses the placenta, and is excreted in breast milk. 3 
Tetracyclines also form tetracycline-calcium orthophosphate 
complexes in sites of calcification such as developing teeth and 
bone. 3 The bioavailabililty of the doxycycline derivatives, the 
monohydrate free base and the hydrochloride salt (hyclate), 
has been shown to be equivalent. 37 
 According to the FDA, the absorption of doxycycline “is 
not markedly influenced by simultaneous ingestion of food 
and milk,” despite the reduced absorption observed with other 
tetracyclines. However, more recent studies on this subject, 
while limited, have shown that the absorption of doxycyline is 
affected to some degree by food and milk, but the clinical con-
sequence of this is not well understood. Food has been shown 
to decrease serum levels of doxycycline from 4.4 to 4.0 μg/mL, 
but this has not been shown to be clinically significant. 3, 37 Milk 
decreases the absorption of tetracyclines because of chelation 
between the calcium in the milk and tetracyclines, however the 
magnitude of this decrease varies between different tetracy-
cline preparations, and the data for doxycycline is limited. 38, 39 
One single-dose, cross-over study administered doxycycline 
with either water or milk to nine volunteers and found that 
milk decreased the peak plasma drug concentration by 24% 
and that the area under the plasma concentration-time curve 
from 0 to 32 hours decreased by 35%. 39 How this decrease in 
bioavailability translates clinically is not known. Furthermore, 
doxycycline is a lipophilic drug and it is not known if the fat 
content of the food or drink affects its absorption. In these 
studies, the fat content of the food and milk ingested was not 
discussed. Therefore, food taken with doxycycline to prevent 
gastrointestinal side effects is not expected to decrease efficacy 
of the drug; however, there is some limited data that suggests 
that milk reduces the bioavailability of doxycycline, which may 
have a negative impact on drug efficacy as in other tetracy-
clines. Because of absent better data, it would seem prudent 
to caution individuals to avoid milk and other dairy products 
when ingesting their daily doxycycline . Separation of the inges-
tion of doxycycline and ingestion of milk by 2–3 hours (time for 
absorption and peak concentration) should be satisfactory. 
 Unlike other tetracyclines, excretion of doxycycline occurs 
primarily by the gastrointestinal tract and to a much lesser 
extent by the kidneys. 40– 42 Most of a doxycycline dose dif-
fuses from the serosal to the mucosal side of the small bowel. 
Doxycycline is chelated to an inactive form intraluminally and 
is excreted. 41, 43 A very small portion is also concentrated by 
the liver in bile for excretion in feces. 41, 43 Serum half-life of 
doxycycline (15–25 hours) is not affected by impaired renal 
function or hemodialysis, and in patients with renal failure, all 
excretion of doxycyline occurs by the gastrointestinal route of 
excretion. 42, 43 
 There are limited to no data on sex, age, body weight, or 
race differences in the pharmacokinetics of doxycycline. One 
study found no differences between males and females ( N = 14 
males and 14 females). 44 
 Pharmacodynamics.  Although it is known that doxycyline 
is a blood schizontocide, 45 the exact mechanism of action 
is not well defined. In  P. falciparum , doxycycline has been 
 Table 2 
 Efficacy of doxycycline with or without quinine for treatment of  P. falciparum malaria 
Country (population) Study type Sample size/doxycycline dose Duration of treatment Cure rate (95% CI)
United States 
(mixture of immune 
and non-immune) 5 
Challenge, open-label  P. vivax: 4 days 0
1/100 mg twice a day 5 days 0
7 days 0
1/100 mg twice a day 100%
 P. falciparum: 
4/100 mg twice a day
9/100 mg twice a day
West Malaysia (varied, 
children aged 2 months–
8 years) 27 
Challenge, open-label 9/4 mg/kg daily 4 days 44.4%
26/4 mg/kg daily 7 days 84.6%
Irian Jaya, Indonesia 
(non-immune) 26 
Randomized, open-label, 
comparator = CQ ( N = 30) 
and doxycycline + CQ 
( N = 39)
20/100 mg twice a day 7 days  P. falciparum : 64.7% 
(42.0–87.4%)
 P. vivax : 33.3% 
(6.6–59.5%)
Brazil (semi-immune) 28 Randomized, open-label, 
comparator = AL ( N = 28)
31/100 mg twice a day + 500 mg 
quinine every 8 hours
5 days doxycycline 100%
3 days quinine
Pakistan (unknown 
immune status) 29 
Challenge, open-label 100/100 mg twice a day + 10mg/kg 
quinine every 8 hours
7 days doxycycline 100%
3 days
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observed to block the expression of apicoplast genes, lead-
ing to nonfunctional apicoplasts in subsequent progeny, and 
impeding the development of viable parasites. 46 It is also 
thought that doxycycline’s antimalarial actions may be simi-
lar to its bacteriostatic actions of binding to ribosomal sub-
units and inhibiting protein synthesis, but this has only been 
observed in supra-pharmacologic doses. 47 Doxycycline has 
also been observed to have some degree of pre-erythrocytic 
activity in  P. falciparum . 16 Of 55 men given a doxycycline pro-
phylaxis regimen that ended 3 days after travel, 13 developed 
 P. vivax and none developed  P. falciparum . 16 Two other stud-
ies observed breakthroughs to doxycycline prophylaxis for 
 P. falciparum between 2 and 12 weeks after administration of 
medication and for  P. vivax between 4 and 9 weeks. 14, 15 There 
are no data on the causal activity of doxycycline for the other 
species of malaria. On the basis of these studies, the recom-
mended duration of the post-exposure course of doxycycline 
is 4 weeks. Doxycycline has no effect on the hypnozoites of 
the  Plasmodium species. 16, 45 Because of this, when treating 
patients infected with species such as  P. vivax and  P. ovale with 
quinine and doxycycline, a 2-week course of primaquine must 
be added to kill hypnozoites. 48 There is very limited evidence 
on doxycycline’s effect on gametocytes. Only one study was 
found that looked at gametocytemia and doxycycline. In this 
study,  P. vivax gametocytemia increased after treatment with 
doxycycline (from 32% pre-treatment to 44% immediately 
post-treatment) with a median gametocyte clearance time of 
62 hours. 49 Although gametocytemia has no clinical implica-
tions, malaria in an individual being treated with doxycycline 
may still be transmitted through mosquitoes. 
 There is no global consensus on the threshold of suscepti-
bility for use in  in vitro susceptibility testing for doxycycline. 
Traditionally, culture-derived or field  P. falciparum isolates 
are incubated with varying concentrations of drug and inhi-
bition of replication is measured by several methods to yield 
a 50% inhibitory concentration (IC50) at 48, 72, or 96 hours. 
The assay conditions and the drug mechanism of action can 
markedly affect results. 50 Frequently, the incubation time for 
these assays is one cycle of parasite replication or 48 hours, 
but for doxycycline at least 72 hours and preferably 96 hours 
is needed, depending on the assay method, to obtain accu-
rate results. The increased incubation time is required because 
doxycyline has been shown to exert its effect during the first 
48 hours, but is only detectable in second generation parasites 
near the 96 hour time point. 46, 51, 52 However, most studies have 
been limited to 48-hour assays. One study in French Guiana 
suggested an IC 50 cutoff level of 9.6 μM for a 48-hour assay 
and noted that after both quinine and doxycycline were rec-
ommended as first-line malaria treatment in 1995, there was 
an increase of mean IC 50s from 9.6 μM in 1996–1999 to 13.1 μM 
in 2005. 53 Another study examined  P. falciparum samples of 
French patients who traveled to various African countries 
between 1997 and 2006 using a 42-hour assay and found an 
overall mean IC 50 of 9.3 μM with country-specific means rang-
ing between 6.2 and 11.1 μM. 54 The findings of these two stud-
ies found many samples with IC 50s above the suggested 9.6 μM 
threshold. However, these findings are not consistent with 
the relative dearth of reporting of doxycycline failure (when 
taken appropriately either as prophylaxis or treatment) in the 
literature. Another study further identified possible molecu-
lar markers for decreased  in vitro susceptibility to doxycycline 
defined as an IC 50 of 35 μM. 55 
 Resistance of  P. falciparum to doxycycline is not described 
but breakthroughs in prophylaxis have been associated with 
inadequate doses, 14 possibly inadequate serum levels, 11 and 
poor compliance. 56, 57 A clear relationship between the devel-
opment of clinical symptoms with confirmed  P. falciparum 
parasitemia and a serum or plasma level of doxycycline or a 
predictive IC 50 in a well-qualified  in vitro susceptibility assay 
remains to be determined. More studies are needed to exam-
ine emergence of doxycycline resistance and establish a clini-
cally relevant susceptibility threshold. 
 ADHERENCE 
 Adherence to daily doxycycline throughout the period of 
exposure to malaria and for 4 weeks following exposure is 
vital in achieving full effectiveness of doxycycline as a malaria 
prophylactic agent. The effectiveness of doxycycline among 
persons in whom adherence was not enforced was compared 
with persons in whom compliance was enforced. Effectiveness 
was only 89% (78–96%) for all types of malaria compared 
with 99% (94–100%) in soldiers in whom adherence was 
enforced. 13 Because of doxycycline’s short half-life and the 
mechanism of action (asexual parasite killing at the end of 
two cycles of erythrocytic replication or 96 hours) relative to 
that of weekly medications, missing a few doses of doxycycline 
would have greater consequences than being a few days late 
for a medication with a long half-life. 
 Most studies suggest that adherence to daily doxycyline is 
more challenging than adherence to a weekly medication. One 
study reported that full adherence to doxycycline daily (81%, 
 N = 52) was lower than that for weekly mefloquine (98%, 
 N = 344) among United States troops in Somalia; however, it 
was not discussed whether administration of one or both med-
ications was supervised. 19 Another study in Thai soldiers did 
not enforce or observe drug administration and reported that 
adherence (at least 75% of the time) occurred in more than 
70% of men given a weekly drug (Maloprim) and in only 50% 
given doxycycline daily. 17 Survey-based studies of travelers or 
military personnel have found adherence rates for doxycycline 
prophylaxis to be between 70% and 84%. A decrease in adher-
ence over time has also been demonstrated. In Australian 
troops, adherence to daily doxycycline decreased from 60% 
at 2 months to 44% at 4 months. 21 Only one study of French 
soldiers in sub-Saharan Africa comparing daily doxycycline 
to weekly chloroquine-proguanil (CP) found that a decrease 
in adherence occurred over time in both groups regardless of 
regimen. 58 Therefore, studies seem to show that short-term 
adherence to daily prophylaxis is more challenging than for 
a weekly medication, but long-term adherence decreases for 
both daily and weekly prophylactic regimens. 
 SAFETY AND TOLERABILITY 
 General ( Tables 3 10 , 13 –16 , 19 , 20 , 28 , 57 , 58 , 61 –64  and  4 10 , 12 –15 , 19 , 21 , 28 , 57 , 58 , 61 –64 ). 
 Doxycycline is generally well tolerated with GI complaints 
and photosensitivity among the most common adverse events 
(AEs). Most available information on AEs in doxycycline are 
from studies examining doxycycline at prophylactic doses (100 
mg/day), and there is limited information on AEs in doxycycline 
at treatment doses. At prophylactic doses of doxycycline, reports 
of mild and moderate AEs vary widely among studies from 0.6% 
to 84% of the study population. 13, 20, 21, 59– 61 This variation can be 
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 Table 3 
 Mild to moderate adverse events (AEs) associated with doxycycline prophylaxis and treatment * 
Study location (design) Sample size, dose, duration Most frequent AE Comparator AE risk with doxycyline
Prophylaxis
Kenya (RDBPC, 
semi-immune) 10 
55, 100 mg doxycycline 
hyclate daily, 
10 weeks
Events: Azithromycin daily No difference between doxycycline 
and comparatorsAbdominal pain 49
Diarrhea 9 Azithromycin 
weeklyVomiting 6
Vaginitis 5 Placebo
Thailand (RDB, 
non-immune) 62 
119, 100 mg doxycycline 
daily, 5 weeks
Nausea 16.7% MQ No difference between doxycycline 
and MQHeadache 10.7%
Skin rash 10.7%
Dizziness 6.3%
Vomiting 4.4%
Africa (observational, 
non-immune) 63 
188, 100 mg doxycycline 
daily, 4 days
Nausea 33.0% MQ Doxycycline group had significantly 
more nausea, abdominal pain, 
vomiting, drowsiness, headache, 
and dizziness than MQ goup.
Abdominal pain 22.9%
Drowsiness 23.9%
Headache 19.7%
Vomiting 8.5%
Dizziness 7.4%
Rash 0.5%
Irian Jaya, 
Indonesia 
(RDBPC, 
non-immune) 13 
67, 100 mg doxycycline 
daily, 13 weeks
Skin-related 33% MQ Placebo Doxycycline group had significantly 
fewer AE relative to MQ and 
placebo.
Cough 31%
GI symptoms 24%
Headache 16%
Dizziness 9%
Insomnia 6%
Thai-Burmese border 
(RPC, open-label, 
semi-immune, children 
aged 10–16 years) 14 
67, > 40 kg 100 mg 
doxycycline daily, 
< 40 kg 50 mg 
doxycycline daily, 
5 months
Abdominal pain 16% Doxycycline 
half-dose
Full-dose doxycycline more likely to 
have GI symptoms than half dose. 
Full-dose doxycyline less likely to 
have headache and dizziness than 
placebo.
Nausea 12%
Diarrhea 8%
Vomiting 4%
Headache 34.3%
Dizziness 26.8%
Thai-Burmese border 
(R, open-label, 
semi-immune, children 
aged 10–16 years) 15 
95, > 40 kg 100 mg 
doxycycline daily, 
< 40 kg 50 mg 
doxycycline daily, 
9 weeks
Dizziness 27% CQ No difference between doxycycline 
and CQNausea 20%
Headache 17%
Fever 15%
Abdominal pain 8%
Vomiting 7%
Diarrhea 7%
Papua New Guinea (open-
label, non-immune) 16 
55, 100 mg doxycycline 
daily, 3 weeks
Gastrointestinal 24% Doxycycline + PQ No difference between doxycycline 
and doxycycline + PQPhotosensitivity 7.3%
Somalia (observational, 
non-immune) 19 
52, 100 mg doxycycline 
daily, 7 weeks
Gastrointestinal 34.6% MQ Doxycycline had significantly higher 
rates of photosensitivity and gas-
trointestinal events than MQ.
Photosensitivity 21.2%
Lightheadedness 19.2%
Rwanda (observational, 
non-immune) 20 
28, 100 mg doxycycline 
daily, 2 months
Abdominal pain 33.3% MQ Doxycyline had higher rates of AE 
compared with MQ.Fatigue 23.8%
Somalia (observational, 
non-immune) 57 
499, 100 mg 
doxycycline daily, 
varied time periods
Gastrointestinal 17% MQ No significant difference between 
doxycycline and MQ, except MQ 
had more insomnia or nightmares.
Dizziness 10%
Insomnia or nightmares 9%
Sunburn 5%
Sub-Saharan Africa 
(RDB, placebo run-in 
phase, non-immune) 61 
153, 100 mg doxycycline Neuropsychological 24% MQ Doxycycline had less neuropsycho-
logical events than mefloquine, and 
less adverse skin events than CQ + 
proguanil. No increased risk of vag-
inal candidiases with doxycycline.
Gastrointestinal 14% CP
Skin itching, reddening 5%
Skin and vaginal itching, 
abnormal discharge 9%
Atovaquone and 
Proguanil
Chad and Gabon 
(randomized groups, 
non-immune) 58 
275, 100 mg doxycycline 
monohydrate daily, 
5 months
Events: CP Doxycycline had significantly less 
diarrhea, epigastralgia, mouth 
ulcers, urticaria, pruritis, rash, and 
sun sensitization than CP. 
No statistical difference in nausea 
and vertigo.
Diarrhea 52
Epigastralgia 46
Nausea 30
Vertigo 14
Mouth ulcers 11
Pruritis 11
Skin rash 9
Sun sensitization 4
Varied countries 
(observational, 
non-immune) 64 
228, 100 mg doxycycline 
daily, at least 
6 months
Gastrointestinal 35% MQ Doxycycline had a higher proportion 
of skin, vaginal, and gastrointestinal 
events than MQ and CQ.
Skin and vaginal 34% CQ
Neuropsychologic 30%
Treatment
Brazil (R, open-label, 
semi-immune) 28 
31, 100 mg doxycycline 
twice a day for 5 days + 
500 mg quinine every 
8 hours for 3 days
Upper abdominal 
pain 41.4%
AL Frequency of AE were similar for 
both doxycycline and AL.
Nausea 34.5%
Vomiting 27.6%
Asthenia 27.6%
Headache 27.6%
 *  MQ = mefloquine; GI = gastrointestinal; CQ = chloroquine; PQ = primaquine; CP = chloroquine-proguanil; AL = artemether/lumefantrine . 
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explained in part because of a high background rate of non-spe-
cific symptoms experienced by both non-immune travelers and 
semi-immune study subjects in malaria endemic areas, differing 
definitions of mild and moderate AEs, use of different salts and 
formulations of doxycycline, and different study populations. 
 Reports of AEs of doxycycline at treatment doses (100 mg 
twice a day) are very limited because studies often exam-
ine malaria treatment with doxycycline in combination with 
another drug such as quinine, and it is difficult to determine 
if symptoms are related to doxycycline alone, malaria, the 
accompanying drug, or because of a drug-drug interaction. 
One randomized, open-label study comparing treatment of 
malaria with doxycycline and quinine versus artemether-lume-
fantrine found that at least one AE was reported in 93.5% of 
patients treated with quinine-doxycycline and 89.2% of those 
treated with artemether-lumefantrine; statistically similar pro-
portions. 28 No serious AEs were noted in both groups. 28 
 Gastrointestinal adverse events.  Gastrointestinal symptoms 
are usually mild to moderate and include nausea (4–33%) and 
abdominal pain (12–33%). 13– 15, 19, 20 , 58 , 62 , 63  Nausea has been noted 
to be more common when doxycycline is ingested without 
food. 13, 21 Vomiting (4–8%) and diarrhea (6–7.5%) are less com-
monly reported. 13– 15, 62, 63 The GI symptoms requiring a change in 
medication have been reported infrequently (0.2–6.4%). 12, 20, 21 
 Doxycycline and other tetracyclines are believed to be the 
most common cause of drug-induced esophageal disorders. 64, 65 
It is thought that long transit times of the pills in the esoph-
agus contributes to mucosal inflammation and that inges-
tion of a sufficient amount of fluid, taking the pill while in an 
upright position, and avoiding taking the pill before bedtime 
could decrease the transit time and prevent inflammation. 65, 66 
Doxycycline has been implicated in esophagitis; among United 
States military personnel returning from Somalia, 4 of 499 
(0.8%) who took daily doxycycline developed odynophagia 
with dehydration requiring hospitalization. 57 One other study, 
a shipboard survey, found esophagitis in 1 of 188 persons tak-
ing doxycyline prophylaxis. 63 
 The effect of various doxycycline salts and formulations such 
as oral suspensions, tablets, capsules, and enteric-coated tablets 
are likely quite significant in their ability to cause GI adverse 
events. Gelatin capsules have been observed to be more sticky 
than tablets, delaying transit time or even adhering to the esoph-
ageal lining, and this is affected by the amount of fluids ingested 
with the pills. 65, 67 Enteric-coated formulations are available 
 Table 4 
 Severe adverse events (AE) associated with doxycycline prophylaxis and treatment 
Study location (design) Sample size, dose, duration Severe AE Discontinued because of AE
Prophylaxis
Kenya (RDBPC, 
semi-immune) 10 
55, 100 mg doxycycline 
hyclate daily, 10 weeks
Recurrent vaginitis 1 1 withdrew
Thailand (RDB, 
non-immune) 62 
119, 100 mg doxycycline 
daily, 5 weeks
None None
Gabon and Central African 
Republic (non-immune) 12 
171, 100 mg doxycyline 
hyclate daily, 4 months
Gastrointestinal side 
effects 11
11 withdrew
Africa (observational, 
non-immune) 63 
188, 100 mg doxycycline 
daily, 4 days
Esophagitis 1 1 discontinued, requiring further 
evaluation and treatment
Irian Jaya, Indonesia 
(RDBPC, non-immune) 13 
67, 100 mg doxycycline 
daily, 13 weeks
None None
Thai-Burmese border 
(semi-immune, children 
aged 10–16 years) 14 
67, 100 mg doxycycline 
daily, 5 months
None None
Thai-Burmese border 
(R, open-label, semi-immune, 
children aged 10–16 years) 15 
95, > 40 kg 100 mg doxycycline 
daily, < 40 kg 50 mg doxycycline 
daily, 9 weeks
None None
Rwanda (observational, 
non-immune) 19 
28, 100 mg doxycycline 
daily, 2 months
Abdominal pain 1 1 discontinued
Somalia, Cambodia 
(observational, 
non-immune) 21 
900, 100 mg daily, 4 months, all 
received primaquine eradication 
course after travel
Sun sensitization 13 15 discontinued
Gastroinestinal 
problems 2
Somalia (Observational, 
non-immune) 57 
499, 100 mg doxycycline daily, 
varied time periods
Odynophagia 4 4 discontinued, required 
hospitalization because of 
dehydration
sub-Saharan Africa 
(RDB, placebo run-in 
phase, non-immune) 61 
153, 100 mg monohydrate daily, 
7–9 weeks
Skin and vaginal itching, 
abnormal discharge 4
5 withdrew, did not 
specify which AE
Skin itching, reddening 3
Gastrointestinal 3
Neuropsychological 1
Chad and Gabon 
(randomized groups, 
non-immune) 58 
275, 100 mg doxycycline 
monohydrate daily, 
5 months
Gastrointestinal effects 9 15 withdrew
Headache 5
Sun sensitization 1
Varied countries 
(observational, 
non-immune) 64 
228, 100 mg doxycycline 
daily, at least 6 months
Gastrointestinal 11 Did not specify. Regimen changes 
caused by AE was lower 
among those taking doxycycline 
than those taking CQ or MQ.
Skin and vaginal 9
Neuropsychologic 5
Treatment
Brazil (R, open-lab, 28  
semi-immune) 61 
31, 100 mg doxycycline twice a 
day for 5 days + 500 mg 
quinine every 8 hours for 3 days
Vomiting 1 1 withdrew
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and may decrease GI side effects. One double-blind, placebo-
controlled, multiple-dose cross-over study compared the inci-
dence of GI side effects of enteric-coated doxycycline hyclate 
pellets in capsules (Doryx, Parke-Davis, Morris-Plains, NJ) 
and doxycycline hyclate powder in capsules (Vibramycin, 
Pfizer, New York), the enteric-coated capsule formulation pro-
duced statistically significantly fewer episodes of nausea, vom-
iting, abdominal discomfort, and decreased appetite than did 
the non-enteric-coated capsules. 68 Differences in GI adverse 
events between doxycycline salts may exist. In the majority of 
studies in which doxycycline has been used for malaria pro-
phylaxis, the source of doxycycline, the salts used, and the 
formulation was not reported. Because the exact active drug 
ingredient and the formulation used seems to affect the inci-
dence and severity of GI adverse events, rates between stud-
ies are difficult to compare. However, one study 12 examining 
efficacy of doxycycline hyclate in the French Army noted a 
6% withdrawal rate caused by GI AEs and attributed this to 
the hyclate salt acidity and capsule form. Fewer withdrawals 
caused by GI AEs (1.5% and 4.9% at two study sites) were 
observed in a follow-up study 58 looking at tolerability of doxy-
cycline monohydrate. Although data are limited, it appears 
that enteric-coated hyclate formulations and monohydrate 
salts are better tolerated in terms of GI AEs than standard 
hyclate capsules or tablets. 
 Photosensitivity.  An erythematous rash in sun-exposed 
areas has been reported to occur in 7.3–21.2% of persons 16, 19, 57 
taking doxycycline for malaria prophylaxis. One study exam-
ined the tolerability of various malaria prophylactic regimens 
and found that doxycycline did not cause a significantly higher 
percentage of all skin events (photosensitivity not specified) 
when compared with other antimalarials. The rash resolves 
upon discontinuation of the drug. A study of 106 acne patients 
taking daily doxycycline found a high incidence (35.8%) of 
light-sensitive rash and suggested that the phenomenon is 
dose related; 20% of patients taking 150 mg/day of doxycy-
cline developed a light-sensitive rash, whereas 42% of those 
taking 200 mg/day were affected. 69 It is suggested that patients 
with lighter complexions (Fitzpatrick skin types 1 and 2) may 
be more susceptible to doxycycline photosensitivity than 
patients with darker skin pigmentation. 70 Both ultraviolet A 
(UV-A) and ultraviolet B (UV-B) radiation have been impli-
cated. 71 Although the mechanism of the phototoxic reaction 
has not been fully elucidated, it is believed to be mediated by 
excited-state singlet oxygen and free radicals after irradiation 
with UV-A radiation, thereby causing selective injury to mito-
chondria, within which doxycycline and other tetracyclines 
are localized. 72 Patients developing photosensitivity should 
be advised to stop taking doxycycline. Avoiding sun exposure, 
wearing protective clothing, and using a broad spectrum (pro-
tection against both UV-A and UV-B radiation) sunscreen 
can lower the risk of photosensitivity. 73, 74 
 Vulvovaginitis.  Antibiotics such as tetracyclines are believed 
to suppress vaginal bacterial flora, resulting in overgrowth 
of candida. 75 A recent  in vitro study found that tetracycline 
may also enhance  Candida albicans virulence factors, but 
the authors note that it is still unclear as to what degree this 
contributes to clinical vaginitis. 76 Increased colonization with 
 C. albicans after taking tetracyclines has been shown. 75, 77, 78 
After a 3-week course of tetracycline, one study observed that 
the percentage of women with vaginal cultures positive for 
 C. albicans increased from 7% to 24%. 77 Another study had 
similar findings for both tetracycline and minocycline. 78 Despite 
this increase in yeast colonization, both studies found that 
only a small percentage of women with positive candidal vagi-
nal cultures had symptoms of vulvovaginitis. 77, 78 In fact, other 
studies have found that only a small percentage of women 
develop clinical vulvovaginitis after taking tetracyclines. 10, 79 
In women taking tetracycline for acne, symptomatic vaginitis 
was observed in 5%. 79 In another study, only one of 21 (4.8%) 
women on daily doxycycline withdrew from the study because 
of repeated episodes of vaginitis. 10 Another study did not find 
an increased risk for vaginal candidiasis with doxcycyline. 61 Of 
note, reporting of vaginitis as an adverse drug reaction spe-
cifically to doxycycline when taken as malaria prophylaxis is 
limited because vaginitis is often included under the category 
of non-specific skin reactions and many of the early studies 
were done in male military personnel. Women taking doxy-
cycline who have a predisposition to candidal vulvovaginitis, 
such as those with diabetes mellitus, past history of recurring 
vulvovaginitis, and those taking oral contraceptives, should 
consider carrying a self-treatment course of antifungals. 
 Other AEs.  There are other AEs that have been reported 
in association with tetracyclines. These include case reports 
of benign intracranial hypertension with tetracycline, minocy-
cline, and doxycycline, but this has been observed to resolve 
upon discontinuation of the medication and has not been 
described in someone taking doxycycyline for malaria pre-
vention. 80– 82 Skin hyper-pigmentation has been reported in the 
dermatological literature associated primarily with minocy-
cline, and seems to mainly occur with long-term use and usu-
ally fades slowly after discontinuing treatment. 83– 88 Only one 
case report mentions skin hyper-pigmentation associated with 
doxycycline in a patient who had taken 1 g dose of doxycy-
cline daily for 12 years. 89 Other AEs mentioned in case reports 
associated with tetracyclines include postinflammatory elas-
tolysis and tooth discoloration in an adult with long-term 
use (12 years). 90, 91 Central nervous system symptoms such 
as vertigo and ataxia have been more frequently associated 
with minocycline as compared with doxycycline because of 
minocycline’s greater lipid solubility. 92  Clostridium difficile -
associated diarrhea (CDAD) has been reported in three 
patients taking doxycycline for malaria prophylaxis for 
between 2 and 6 weeks. 93 A more recent case-control study 
examining antibiotic use and subsequent CDAD found doxy-
cycline to be protective, however, this study did not examine 
the duration and dose of antibiotic therapy. 94 
 Comparative tolerability.  There are varying reports of the 
comparative tolerability of doxycycline. Several non-random-
ized survey-based studies in military personnel have found 
a higher occurrence of photosensitivity, GI symptoms, head-
ache, and light-headedness with doxycycline as compared with 
mefloquine, whereas others have found that doxycycline is 
better tolerated than mefloquine. 19, 20, 57, 63, 64 The type of doxy-
cycline salt and formulation used in these studies were rarely 
reported, making it difficult to distinguish if the comparative 
tolerability of doxycycline to other antimalarials was affected 
by the type of doxycycline preparation used. One randomized, 
open-label trial found that while more participants taking 
doxycycline monohydrate withdrew from the study, their rates 
of adherence were higher compared with those taking chloro-
quine/progruanil. 58 However, another randomized, open-label 
trial found doxycycline (unspecified salt) to be tolerated as 
well as chloroquine. 15 
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 The strongest evidence for doxycycline’s relatively good 
tolerability is found in three randomized, double-blinded tri-
als. Two of the studies found little or no difference in the fre-
quency of AEs between doxycycline (unspecified salt) and 
mefloquine, and all AEs were mild and transient. 13, 62 In the 
third study, doxycycline monohydrate, atovaquone/proguanil, 
mefloquine, and chloroquine plus proguanil were compared 
( N = 623 evaluable persons). 61 Severity of AEs was graded on a 
scale of 1–4 with 1 being trivial and 4 requiring hospitalization. 
Although no significant differences were seen between groups 
for mild (grade 1) or severe (grade ≥ 3) AEs, moderate AEs 
(grade = 2) differed significantly between groups. Moderate 
AEs were reported by 45% of chloroquine/proguanil users, 
42% of mefloquine users, 33% of doxycycline monohydrate 
users, and 32% of atovaquone/proguanil users. Although not 
statistically significant, doxycycline monohydrate had the low-
est incidence of severe adverse events (6%) of all regimens. Of 
these severe events, one-third was skin reactions. There were 
no significant differences in the rates of skin reaction or GI 
events between any of the regimens. When compared with the 
other medications, doxycycline monohydrate had an interme-
diate proportion of withdrawals, but this proportion did not 
differ significantly between the treatment arms. The authors 
concluded that of all four regimens, doxycycline monohydrate 
was one of the best tolerated. 61 Overall, the evidence suggests 
that doxycycline is tolerated as well as other malaria prophy-
lactic regimens. 
 CONTRAINDICATIONS 
 Doxycycline is contraindicated in anyone with a history of 
hypersensitivity to any of the tetracyclines. 
 Duration of Use.  There are very limited studies on the use 
of doxycycline for malaria prophylaxis for a prolonged period 
of time. The current FDA product insert approves use for up 
to 4 months. 95 One study surveyed 600 military personnel in 
Cambodia who took prophylactic doses of doxycycline for 
12 months and 900 men deployed to Somalia for 4 months. 21 
Doxycycline was well tolerated; only 7 (0.6%) in Cambodia 
and 15 (1.7%) in Somalia discontinued medication because 
of adverse events related to GI problems and photosensitiv-
ity. Another study surveyed 228 U.S. Peace Corps volunteers 
who had taken doxycycline prophylaxis for an average of 
19 months. 64 Of these, 45 (20%) changed medications caused 
by adverse events such as GI symptoms, pruritic skin reactions, 
photosensitivity, and vaginal yeast infection. Compared with 
mefloquine in which 28% of respondents changed medica-
tion caused by adverse events, doxycycline was better toler-
ated. Of note, in these two studies, the types of adverse events 
reported were the same as those in persons using doxycycline 
for shorter periods of time. However, both studies used post-
trip surveys and did not have information on adherence for all 
participants. 
 Although long-term safety and tolerability studies have not 
been performed with doxycycline as a malaria chemoprophy-
laxis, similar drugs in the same class, tetracycline and minocy-
cline, have been used in equivalent doses (less than 1 g/day for 
tetracycline, 50 mg/day to 100 mg twice a day for minocycline) 
for a few months to several years in the treatment of vari-
ous dermatological conditions. This suggests that doxycycline 
can be used for long-term malaria chemoprophylaxis. When 
used at this dosage, tetracyclines were found in some studies 
to cause no abnormalities in renal and hepatic function when 
taken for as long as 5 years and in one study, for as long as 
13 years. 96– 98 There have, however, been several case reports 
of minocycline-associated autoimmune hepatitis and systemic 
lupus erythematosus-like syndrome in persons who used mino-
cycline at 100 mg or more daily for more than 1 year. 99– 103 Of 
note, doxycycline users were not found to have an increased 
risk of hepatotoxicity in one matched case-control study. 104 
Scleral, dental, and dermal hyperpigmentation has also been 
reported in patients taking long-term minocycline as early as 
1 month after initiation of treatment, 86, 87, 105, 106 but this hyper-
pigmentation has been shown to fade after discontinuation of 
the medication. 86, 87, 105, 106 In a 2-year, double-blind comparison 
of minocycline (100 mg twice a day) and hydroxychloroquine 
for the treatment of rheumatoid arthritis, only 10% of patients 
withdrew because of rash or GI symptoms. 106 Overall, these 
case reports and studies observed rare to occasional adverse 
events associated with long-term use of other tetracyclines. 
 THERAPEUTIC INDEX AND OVERDOSE 
 Tetracycline antibiotics are relatively non-toxic. Exceeding 
the recommended dosage of doxycycline may result in 
increased incidence of ADRs. There has been one case report 
of an individual who took 1 g of doxycycline/day for 12 years. 89 
He was found to have hepatocellular necrosis with cholesta-
sis, nephrotoxicity, leucopenia with anemia, skin hyperpig-
mentaion, and intermittent supraventricular tachycardia with 
sporadic Wenckebach heart block. He was not found to have 
any of the common doxycycline side effects such as GI symp-
toms or photosensitivity. After discontinuation of the drug, 
most of these symptoms resolved with the exception of resid-
ual cutaneous hyperpigmentation, relapsing cardiac arryth-
mias, and increased bilirubin. 89 In the case of overdosage, the 
medication should be discontinued and supportive measures 
and symptomatic treatment instituted. 95 
 DRUG INTERACTIONS 
 Doxycycline was introduced into clinical practice long 
before the recognition of drug-drug interactions and without 
currently required pre-licensure  in vitro or  in vivo studies. 107 
The potential for drug-drug interactions with doxycycline 
based on a full panel of  in vitro studies with phase I metab-
olizing enzymes (cytochrome P450), phase II enzymes, and 
transporter mediated drug interactions has not been reported. 
On the basis of a single  in vitro study showing that doxycy-
cline inhibits the metabolism of quinine to 3-hydroxyquinine, 
the major metabolic pathway known to be enzymatically cat-
alyzed by CYP 3A4, doxycycline is thought to be a modest 
inhibitor of CYP 3A4. Because CYP 3A4 is the most com-
mon phase 1 enzyme involved in drug metabolism, the spec-
trum of potential drug-drug interactions is wide and is not 
well defined. Furthermore,  in vitro interactions do not always 
predict clinically significant effects. Information on drug-drug 
interactions with doxycycline is based on clinical observations 
and predictions are based on limited data accumulated over 
the last 40 years of clinical use, as described below. 
 Tetracyclines can chelate divalent and trivalent cations in 
certain medications that may cause a decreased absorption of 
the tetracycline and the medication when given concurrently. 3 
These medications include antacids with aluminum, calcium 
526 TAN AND OTHERS
or magnesium, laxatives with magnesium, and oral iron prepa-
rations. Other medications decreasing absorption of tetracy-
clines include antidiarrheal agents containing kaolin, pectin, 
or bismuth subsalicylate. Medications such as these should be 
taken a few hours before doxycycline. 3, 108 
 Although a possible interaction with oral contraceptives 
(OCs) has been cited in older literature, 3 current evidence 
has not supported this information. 109– 111 The overall OC fail-
ure rate in women who were also treated with antibiotics was 
found to be 1.2–1.6%, and this failure is thought to occur in 
individuals in whom plasma concentrations of ethinyl estra-
diol are decreased. 110 Furthermore, the failure rate observed in 
concurrent administration of OC and antibiotics is well within 
the 1–3% failure rate observed with typical OC use. 110, 112 
Therefore, recent evidence suggests that doxycycline can be 
used concurrently with OCs without leading to a higher rate of 
contraceptive failure than would be expected among OC users 
not currently taking antibiotics. 
 Tetracyclines may potentiate the effect of oral anticoagu-
lants by impairing the use of prothrombin and decreasing 
vitamin K production by intestinal bacteria. 3 The literature is 
limited, and there has been only one case report of a woman 
well controlled on warfarin, who developed an increased inter-
national normalized ratio and retroperitoneal bleeding when 
doxycycline was administered. 113 It was hypothesized that in 
addition to the aforementioned mechanism, competition with 
protein binding or the occurrence of an inhibitory mechanism 
by the cytochrome P450 system could be factors. 113 Patients 
on oral anticoagulants should have their prothrombin times 
monitored closely and dosage adjusted as needed. 3 
 As a bacteriostatic drug, tetracyclines may interfere with the 
bactericidal action of aminoglycosides and penicillin 3, 36 but this 
has only been reported  in vitro , 114 and may not be of clinical 
significance. Doxycycline can be used concurrently with cipro-
floxacin and azithromycin, two antibiotics commonly given to 
travelers for self-treatment of traveler’s diarrhea. 
 Fatal nephrotoxicity has been reported in patients receiving 
methoxyflurane anesthesia and tetracycline. 115– 117 Although 
this has not been observed with doxycycline, specifically, con-
current use of tetracyclines and methoxyflurane anesthesia is 
not recommended. 
 Concurrent use of digoxin and oral antibiotics such as tet-
racyclines may increase serum digoxin concentrations in 
some individuals. It is believed that the tetracycline alters 
gut flora, diminishing digoxin conversion to inactive metabo-
lites, resulting in increased serum digoxin concentrations. 118, 119 
However, the data is limited and there have been no reports 
of toxicity caused by concurrent administration of digoxin and 
tetracyclines. 
 Barbiturates, carbamazepine, and phenytoin are believed to 
decrease the half-life of doxycycline by inducing microsomal 
enzyme activity. 41, 120 It has been suggested to double the 
doxycycline dosage (take twice daily) in those taking anti-
epileptics. 120 
 Theoretically, antibiotics such as doxycycline could 
decrease the effectiveness of the oral typhoid vaccine Ty21a 
by preventing replication of the live attenuated  Salmonella 
Ty21a bacteria used in the vaccine. However, there is no 
experimental data in animals or humans to support this 
position. Nevertheless, most experts advise not giving 
doxycycline within 24 hours of the oral typhoid vaccine. 1 
Because the immunization schedule for oral typhoid vaccine 
is recommended to be completed at least 1 week before poten-
tial exposure to  Salmonella typhi , 121 there should be no oppor-
tunity for interaction between the oral typhoid vaccine and 
doxycycline in most travelers. 
 There are no known drug interactions between doxycycline 
and antiretrovirals. 
 SPECIAL POPULATIONS 
 Children.  Doxcycycline is not recommended for children 
< 8 years of age because tetracyclines have been shown to 
cause permanent discoloration of the teeth. 122, 123 Tetracyclines 
form a complex with calcium orthophosphate that becomes 
incorporated into bones and teeth undergoing calcification. 124 
Tooth discoloration is permanent because remodeling and cal-
cium exchange do not occur after calcification is completed. 
Some believe teeth staining is related to the total dose of tet-
racycline 122, 123 while others argue that it is caused by repeated 
courses. 125, 126 It is also thought that timing of tetracycline 
administration during tooth development, especially during 
early dentin formation, determines the degree of discolor-
ation. 126 By 8 years of age the dentin and calcium-rich enamel 
has formed on almost all teeth (except wisdom teeth), and 
therefore doxycycline can be taken after this age. There are 
some who recommend that the lower age limit for taking 
doxycycline should be 12, when most children have had their 
primary teeth replaced by their adult dentition. Doxycycline, 
however, may cause less tooth discoloration than other tetra-
cyclines because it has a lower binding affinity to calcium. 127, 128 
In fact, one study found that a short course of doxycycline 
given to children for Rocky Mountain spotted fever did not 
cause clinically significant staining of teeth. 129 
 Of note, doxycycline is considered the drug of choice for 
treatment of infections in which the risks of tooth discolor-
ation is outweighed by the benefit of disease treatment, such 
as presumed or confirmed rickettsial infection, ehrlichiosis, 
murine typhus, or inhalational anthrax. 129– 135 Because there 
are other drug alternatives for treatment and prophylaxis of 
malaria in children < 8 years of age, use of doxycycline is not 
recommended. 
 The formation of the tetracycline and calcium orthophos-
phate complex in developing bone is thought to cause growth 
retardation, but the evidence is limited. Decreased long bone 
growth rate has been observed in premature infants given 
tetracycline but is reversible upon discontinuation of the 
drug. 136, 137 There are no studies showing tetracycline-induced 
growth retardation in term infants or older children. 
 Pregnant women.  Doxycycline is a category D drug; there-
fore, the possibility of pregnancy in a woman of childbearing 
age must be addressed before administration of this drug. 124 
Doxycycline is not recommended for malaria prevention 
or treatment in pregnancy, except for the treatment of life-
threatening multidrug-resistant  P. falciparum when no other 
treatment options are available. No congenital malformations 
have been associated with its use, 124, 138, 139 and some limited evi-
dence suggests that use of doxycycline in the first trimester 
might not cause adverse events in the fetus. 140, 141 However, tet-
racyclines cross the placenta and have been observed to cause 
discoloration of teeth when given during the second or third 
trimester of pregnancy. 142, 143 Because deciduous teeth begin 
to calcify at 5–6 months gestation, use of tetracycline during 
this time can result in staining. 124 Additionally, on the basis of 
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observed retardation of bone growth in premature infants, 137 
there are concerns of inhibition of bone growth in the fetus. 
 Tetracyclines have also been associated with fatal liver 
necrosis in pregnancy. 138, 144, 145 These reports, however, are rare 
and have usually involved higher doses of doxycycline than 
those used for malaria prophylaxis and treatment. 146 
 For women planning on becoming pregnant, there is no 
need to wait a specific period of time after doxycycline use 
before attempting to conceive, based on the short half-life 
(15–25 hours) of the drug. 3, 36 If women or their health care 
providers wish to decrease the amount of doxycycline in the 
body before conception, after 6 half-lives (3–6 days) only 2% 
of the doxycycline remains in the body. 147 
 Breastfeeding.  Data are extremely limited on the use of 
doxycycline in breastfeeding women. Doxycycline is excreted 
in breast milk at concentrations 30–40% of that found in 
maternal blood, 138, 148 and it is thought that the drug’s absorp-
tion by infants is inhibited by the calcium in the breast milk. 
Furthermore, tetracycline was undetectable in breastfed 
infants whose mothers were taking tetracycline. 149 Tetracycline 
has also been assessed by the American Academy of Pediatrics 
to be compatible with breastfeeding. 149 Although data for 
doxycycline and breastfeeding are limited, most experts feel 
that the theoretical possibility of teeth discoloration and 
bone growth inhibition in the nursing baby would be remote. 
Concerned mothers or doctors may consider alternative drugs 
such as mefloquine, or for mothers nursing babies weighing 
more than 5 kg, atovaquone/proguanil. 
 Medical conditions.  In patients with impaired renal or 
hepatic function, the dose of doxycycline does not have to be 
adjusted because it is excreted as an inactive chelated product 
by a complex process of back diffusion in the small intestine. 150 
Additionally, the clearance of doxycycline has been shown to 
be similar to those with normal renal function and in those 
with renal failure. 151 
 In patients with seizure disorders in whom mefloquine is 
contraindicated, doxycycline can be given as an alternative. 147 
However, antiepileptics have been noted to shorten the half-
life of doxycycline and dosing adjustments must be made 
accordingly (see Drug Interactions section). 
 Doxycyline (Vibramycin) syrup contains metabisulfite, 
which can cause allergic reactions, including anaphylaxis and 
asthmatic episodes in susceptible individuals. 3 
 Persons being treated for skin conditions with minocycline 
and who are in need of malaria prophylaxis should stop mino-
cycline and start doxycycline. There is more data on the anti-
malarial efficacy of doxycycline compared with minocycline, 
therefore minocycline is not recommended as a replacement 
for doxycycline. Additionally, there have been case reports 
of autoimmune hepatitis in persons taking 100 mg or more 
of minocycline daily, whereas doxycycline has been observed 
to have less hepatotoxicity than other tetracyclines and less 
adverse events than minocycline. 100, 101, 104, 152 After completion 
of doxycycline for malaria prophylaxis, minocycline can be 
resumed. 
 COST 
 The drug cost for doxycycline varies by doxycycline salt, 
enteric formulation, or brand name versus generic. One arti-
cle examining the cost considerations of malaria chemopro-
phylaxis looked at the average wholesale price (prices from 
2006) of various antimalarial medications and found that 
generic doxycycline hyclate was much cheaper (100 mg, 
US $0.25 per dose) than generic doxycycline monohydrate 
(100 mg, $2.13 per dose) and that generic doxycycline mono-
hydrate was much cheaper than the brand name (Vibratabs, 
doxycycline monohydrate 100 mg, $4.51 a dose). 153 In this 
same work, the direct costs of various malaria chemoprophy-
laxis regimens were compared. For a 14-day stay, including 
pre- and post-exposure doses, the drug cost for prophylaxis 
was $11.00 for generic doxycycline hyclate compared with 
$84.64 for mefloquine and $113.39 for atovaquone/progua-
nil. 153 Using generic doxycycline monohydrate brings up the 
cost of prophylaxis to that of mefloquine, and using brand 
name doxycycline monohydrate brings the costs up even fur-
ther. To look at more recent costs, prices of antimalarials were 
examined online for the average wholesale price. A full course 
of malaria prophylaxis for a 14-day stay in a malaria-endemic 
area costs $18.49 for generic doxycycline hyclate capsules, 
$65.79 for generic doxycycline monohydrate capsules, $122.50 
for Vibratabs, $406.35 for Doryx (enteric-coated doxycycline 
hyclate), $80.48 for mefloquine, and $159.94 for atovaquone/
proguanil. 154 
 EXCHANGING DOXYCYCLINE 
FOR OTHER ANTIMALARIALS 
 There is very limited information on the best regimen for 
changing from doxycycline to other antimalarials, and rec-
ommendations for doing so are based on considering sev-
eral issues such as drug-drug interactions, half-life differences, 
and differences in mechanism of action. If changing between 
atovaquone/proguanil and doxycycline, note that the current 
atovaquone-proguanil label lists a pharmacokinetic interac-
tion of “concomitant treatment (of  P. falciparum malaria) 
with tetracycline (with atovaquone) has been associated with 
approximately a 40% reduction in plasma concentrations of 
atovaquone,” 155 however, there are no accessible published 
studies that support this. On the contrary, early  in vitro stud-
ies of atovaquone plus doxycycline and atovaquone plus tet-
racycline showed potentiation between the two drugs, which 
was later confirmed in clinical studies by improved cure rates 
when compared with atovaquone alone. 156– 158 Therefore, if 
changing from doxcycyline to atovaquone/proguanil for 
malaria treatment or prophylaxis, doxycycline can be stopped 
and atovaquone/proguanil started at the same time. However, 
the recommended length of the post-trip course of prophylac-
tic medications may change because the drugs target different 
stages of the  Plasmodium life cycle. The Centers for Disease 
Control and Prevention (CDC) currently recommends that 
the atovaquone/proguanil is continued for up to 4 weeks after 
leaving the endemic area depending on when the change was 
made. 1 If changing from atovaquone/proguanil to doxycycline 
at any time, a full prophylactic course of doxycycline should 
be taken (for the duration of the stay and 4 weeks after depar-
ture). Changing from doxycycline to other antimalarials such 
as chloroquine or mefloquine will be impacted by the differ-
ence in half-lives of these medications. Doxycycline’s half-
life of 15–25 hours is much shorter than that of chloroquine 
(6–60 days) and mefloquine (2–3 weeks). 1 A change from 
doxycycline to chloroquine or mefloquine before travel would 
still require that chloroquine and mefloquine are taken 1 and 
2 weeks before exposure, respectively, to attain effective blood 
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concentrations before travel. It is not recommended to change 
from doxycycline to chloroquine or mefloquine during or 
after travel because effective blood concentrations will not 
be achieved for a few weeks, leaving the traveler unprotected 
during this time. 
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